Friday Five: Key Regulatory Updates in Pharma
Decision brief
Answer first · skim in under a minute
This article covers significant regulatory updates impacting the pharmaceutical industry, including GSK's breakthrough in hepatitis B and Eli Lilly's advancements in prevention.
This Friday Five corrects the record on Daraxonrasib: Revolution Medicines’ RAS(ON) inhibitor is advancing through FDA expanded access and EMA phased review for metastatic pancreatic cancer, while GSK’s separate bepirovirsen program holds hepatitis B priority review. Here is what regulators disclosed and what remains unproven for BD and investor teams.
Contents11 sections
Key Takeaways
- Daraxonrasib (RMC-6236) is Revolution Medicines’ investigational pan-RAS(ON) inhibitor for PDAC and other RAS-driven tumors—not a GSK hepatitis B asset.
- On May 1, 2026, FDA announced a safe-to-proceed letter enabling an expanded access protocol for previously treated metastatic PDAC.
- On July 7, 2026, Revolution Medicines said EMA CHMP started a phased review of Daraxonrasib while a U.S. rolling NDA nears completion under the Commissioner’s National Priority Voucher pilot.
- Pivotal support comes from Phase 3 RASolute 302 (NCT06625320); GSK’s bepirovirsen has a separate October 26, 2026 PDUFA date for chronic hepatitis B.
What is Daraxonrasib, and why was the old framing wrong?
Daraxonrasib is an investigational oral RAS(ON) multi-selective, non-covalent tri-complex inhibitor designed to suppress signaling from multiple oncogenic RAS variants. Revolution Medicines is the sponsor. Earlier drafts of this roundup wrongly tied the molecule to GSK’s hepatitis B antisense program; that claim is deleted because primary sources identify bepirovirsen (GSK3228836) as the GSK chronic hepatitis B candidate and Daraxonrasib as an oncology RAS inhibitor.
Context: Revolution Medicines GlobeNewswire release on EMA phased review.
What did FDA say about Daraxonrasib expanded access?
On May 1, 2026, FDA announced it issued a “safe to proceed” letter so Revolution Medicines can start an expanded access treatment protocol for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The agency said it received the request on April 28 and signed it on April 30. FDA also noted Breakthrough Therapy and Orphan Drug designations and that the company intended an NDA under the Commissioner’s National Priority Voucher pilot.
Primary: FDA press announcement on Daraxonrasib expanded access.
How is EMA reviewing Daraxonrasib after RASolute 302?
On July 7, 2026, Revolution Medicines said EMA’s CHMP started a phased review of Daraxonrasib data for pancreatic cancer, evaluating packages as they become available before a full marketing authorization application. The company said Daraxonrasib holds EMA orphan designation for pancreatic cancer and is flagged as high priority under EMA’s Cancer Medicines Pathfinder project.
The same release said the U.S. rolling NDA under the Commissioner’s National Priority Voucher pilot was nearing completion, supported by Phase 3 RASolute 302 results in previously treated metastatic PDAC. FDA has granted Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic PDAC harboring G12 mutations, per the company statement.
- Sponsor: Revolution Medicines (Nasdaq: RVMD)
- EMA action disclosed: July 7, 2026 phased review start
- U.S. pathway cited: rolling NDA + National Priority Voucher pilot
- Indication focus: previously treated metastatic PDAC
What does ClinicalTrials.gov show for RASolute 302?
RASolute 302 (NCT06625320) is a Phase 3, multicenter, open-label, randomized study of Daraxonrasib (RMC-6236) versus investigator’s choice of standard-of-care therapy in previously treated metastatic PDAC. ClinicalTrials.gov lists overall status ACTIVE_NOT_RECRUITING, an actual start date of October 16, 2024, estimated primary completion in June 2026, and expanded-access linkage (NCT07573215) marked AVAILABLE as of the May 29, 2026 update.
Registry: ClinicalTrials.gov NCT06625320 (RASolute 302).
Which GSK hepatitis B program actually has FDA priority review?
GSK’s bepirovirsen—an investigational antisense oligonucleotide licensed from Ionis—was accepted for FDA priority review and granted Breakthrough Therapy Designation for adults with chronic hepatitis B. GSK assigned October 26, 2026 as the PDUFA goal date and noted prior Fast Track designation from February 2024. This program is independent of Daraxonrasib and should not be conflated with the RAS(ON) oncology franchise.
Primary: GSK announcement on bepirovirsen priority review.
What should BD and competitive-intelligence teams watch next?
For Daraxonrasib, the near-term markers are completion of the U.S. rolling NDA package, any FDA filing-acceptance or review-clock disclosure, and how EMA phased review milestones translate into a full MAA timeline. Teams should also track enrollment progress on companion Phase 3 studies in first-line PDAC, adjuvant PDAC, and RAS-mutant NSCLC that Revolution Medicines has described as part of the broader registrational program.
For hepatitis B competitive maps, watch the October 26, 2026 bepirovirsen PDUFA date and whether labeling, if approved, supports a functional-cure claim versus viral suppression alone. Those are separate diligence trees from RAS inhibitor deal models.
What remains unproven?
Public primaries do not yet show an FDA marketing approval for Daraxonrasib, a final PDUFA date for the oncology NDA, or peer-reviewed publication of the full RASolute 302 statistical analysis in this article’s source set. Company language about “unprecedented” survival gains should be treated as sponsor framing until independent publications and regulatory reviews are complete. Do not assume U.S. and EU approval will be simultaneous.
Related NovaPharma coverage
- BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
- GSK’s Blenrep returns to the US market after FDA approves resubmission
- Cardiff Oncology pipeline update: onvansertib trials and FDA meeting catalysts
Frequently Asked Questions
What is Daraxonrasib and who develops it?
Daraxonrasib (RMC-6236) is an investigational oral RAS(ON) multi-selective inhibitor from Revolution Medicines for RAS-driven cancers, including previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). It is not a hepatitis B drug and is not sponsored by GSK.
Has the FDA approved Daraxonrasib?
No. As of July 2026 Daraxonrasib remains investigational. On May 1, 2026 the FDA said it issued a safe-to-proceed letter for an expanded access treatment protocol in previously treated metastatic PDAC, and Revolution Medicines has described a rolling NDA under the Commissioner’s National Priority Voucher pilot.
Which GSK hepatitis B program has FDA priority review?
GSK’s bepirovirsen (GSK3228836), an investigational antisense oligonucleotide for chronic hepatitis B, was accepted for FDA priority review with Breakthrough Therapy Designation and a PDUFA goal date of October 26, 2026. It is distinct from Daraxonrasib.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Daraxonrasib.
Unlock full calendar →GSK pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
